Competitive binding of a benzimidazole to the histone-binding pocket of the pygo PHD finger

ACS Chemical Biology

Volumn 9, Issue 12, 2014, Pages 2864-2874

  Miller, Thomas C R ^a,c   Rutherford, Trevor J ^a   Birchall, Kristian ^b   Chugh, Jasveen ^b   Fiedler, Marc ^a   Bienz, Mariann ^a  

^a MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENZIMIDAZOLE; BENZOTHIAZOLE DERIVATIVE; HISTONE H3; ANTINEOPLASTIC AGENT; BCL9 PROTEIN, HUMAN; BENZIMIDAZOLE DERIVATIVE; CHROMATIN; HISTONE; LIGAND; PROTEIN BINDING; PYGO1 PROTEIN, HUMAN; RECOMBINANT PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR PROTEIN;

ARTICLE; CHEMICAL BINDING; MOLECULAR DOCKING; NUCLEAR MAGNETIC RESONANCE; PROTEIN PROTEIN INTERACTION; SCREENING; X RAY CRYSTALLOGRAPHY; ANTAGONISTS AND INHIBITORS; BINDING COMPETITION; BINDING SITE; CHEMISTRY; CHROMATIN; DRUG DEVELOPMENT; ESCHERICHIA COLI; GENE EXPRESSION; GENETICS; HUMAN; METABOLISM; PROTEIN TERTIARY STRUCTURE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; BENZOTHIAZOLES; BINDING SITES; BINDING, COMPETITIVE; CHROMATIN; CRYSTALLOGRAPHY, X-RAY; DRUG DISCOVERY; ESCHERICHIA COLI; GENE EXPRESSION; HISTONES; HUMANS; LIGANDS; MOLECULAR DOCKING SIMULATION; NEOPLASM PROTEINS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS;

EID: 84919628498     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb500585s     Document Type: Article

References (45)

1. Polakis, P. (2012) Wnt signaling in cancer Cold Spring Harbor Perspect. Biol. 4, a008052
2. Bienz, M. and Clevers, H. (2000) Linking colorectal cancer to Wnt signaling Cell 103, 311-320
3. Clevers, H. and Nusse, R. (2012) Wnt/β-Catenin Signaling and Disease Cell 149, 1192-1205
4. Barker, N., Ridgway, R. A., van Es, J. H., van de Wetering, M., Begthel, H., van den Born, M., Danenberg, E., Clarke, A. R., Sansom, O. J., and Clevers, H. (2009) Crypt stem cells as the cells-of-origin of intestinal cancer Nature 457, 608-611
5. Polakis, P. (2012) Drugging Wnt signalling in cancer EMBO J. 31, 2737-2746
6. Daniels, D. L., Eklof Spink, K., and Weis, W. I. (2001) β-catenin: molecular plasticity and drug design Trends Biochem. Sci. 26, 672-678
7. Sampietro, J., Dahlberg, C. L., Cho, U. S., Hinds, T. R., Kimelman, D., and Xu, W. (2006) Crystal structure of a β-catenin/BCL9/Tcf4 complex Mol. Cell 24, 293-300
8. Fiedler, M., Sanchez-Barrena, M., Nekrasov, M., Mieszczanek, J., Rybin, V., Muller, J., Evans, P., and Bienz, M. (2008) Decoding of methylated histone H3 tail by the Pygo-BCL9 Wnt signaling complex Mol. Cell 30, 507-518
9. Gu, B., Sun, P., Yuan, Y., Moraes, R. C., Li, A., Teng, A., Agrawal, A., Rheaume, C., Bilanchone, V., Veltmaat, J. M., Takemaru, K., Millar, S., Lee, E. Y., Lewis, M. T., Li, B., and Dai, X. (2009) Pygo2 expands mammary progenitor cells by facilitating histone H3 K4 methylation J. Cell Biol. 185, 811-826
10. Miller, T. C., Rutherford, T. J., Johnson, C. M., Fiedler, M., and Bienz, M. (2010) Allosteric remodelling of the histone H3 binding pocket in the Pygo2 PHD finger triggered by its binding to the B9L/BCL9 co-factor J. Mol. Biol. 401, 969-984
11. Thompson, B., Townsley, F., Rosin-Arbesfeld, R., Musisi, H., and Bienz, M. (2002) A new nuclear component of the Wnt signalling pathway Nat. Cell Biol. 4, 367-373
12. Adachi, S., Jigami, T., Yasui, T., Nakano, T., Ohwada, S., Omori, Y., Sugano, S., Ohkawara, B., Shibuya, H., Nakamura, T., and Akiyama, T. (2004) Role of a BCL9-related β-catenin-binding protein, B9L, in tumorigenesis induced by aberrant activation of Wnt signaling Cancer Res. 64, 8496-8501
13. Brembeck, F. H., Schwarz-Romond, T., Bakkers, J., Wilhelm, S., Hammerschmidt, M., and Birchmeier, W. (2004) Essential role of BCL9-2 in the switch between β-catenins adhesive and transcriptional functions Genes Dev. 18, 2225-2230
14. de la Roche, M., Worm, J., and Bienz, M. (2008) The function of BCL9 in Wnt/β-catenin signaling and colorectal cancer cells BMC Cancer 8, 199
15. Deka, J., Wiedemann, N., Anderle, P., Murphy-Seiler, F., Bultinck, J., Eyckerman, S., Stehle, J. C., Andre, S., Vilain, N., Zilian, O., Robine, S., Delorenzi, M., Basler, K., and Aguet, M. (2010) Bcl9/Bcl9l are critical for Wnt-mediated regulation of stem cell traits in colon epithelium and adenocarcinomas Cancer Res. 70, 6619-6628
16. Watanabe, K., Fallahi, M., and Dai, X. (2014) Chromatin effector Pygo2 regulates mammary tumor initiation and heterogeneity in MMTV-Wnt1 mice Oncogene 33, 632-642
17. de la Roche, M., Rutherford, T. J., Gupta, D., Veprintsev, D. B., Saxty, B., Freund, S. M., and Bienz, M. (2012) An intrinsically labile α-helix abutting the BCL9-binding site of β-catenin is required for its inhibition by carnosic acid Nat. Commun. 3, 680
18. de la Roche, M., Ibrahim, A. E., Mieszczanek, J., and Bienz, M. (2014) LEF1 and B9L shield β-catenin from inactivation by Axin, desensitizing colorectal cancer cells to tankyrase inhibitors Cancer Res. 74, 1495-1505
19. Takada, K., Zhu, D., Bird, G. H., Sukhdeo, K., Zhao, J. J., Mani, M., Lemieux, M., Carrasco, D. E., Ryan, J., Horst, D., Fulciniti, M., Munshi, N. C., Xu, W., Kung, A. L., Shivdasani, R. A., Walensky, L. D., and Carrasco, D. R. (2012) Targeted disruption of the BCL9/β-catenin complex inhibits oncogenic Wnt signaling Sci. Transl. Med. 4, 148ra117
20. Edfeldt, F. N., Folmer, R. H., and Breeze, A. L. (2011) Fragment screening to predict druggability (ligandability) and lead discovery success Drug Discovery Today 16, 284-287
21. Filippakopoulos, P. and Knapp, S. (2014) Targeting bromodomains: epigenetic readers of lysine acetylation Nat. Rev. Drug Discovery 13, 337-356
22. Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., Philpott, M., Munro, S., McKeown, M. R., Wang, Y., Christie, A. L., West, N., Cameron, M. J., Schwartz, B., Heightman, T. D., La Thangue, N., French, C. A., Wiest, O., Kung, A. L., Knapp, S., and Bradner, J. E. (2010) Selective inhibition of BET bromodomains Nature 468, 1067-1073
23. James, L. I., Barsyte-Lovejoy, D., Zhong, N., Krichevsky, L., Korboukh, V. K., Herold, J. M., MacNevin, C. J., Norris, J. L., Sagum, C. A., Tempel, W., Marcon, E., Guo, H., Gao, C., Huang, X. P., Duan, S., Emili, A., Greenblatt, J. F., Kireev, D. B., Jin, J., Janzen, W. P., Brown, P. J., Bedford, M. T., Arrowsmith, C. H., and Frye, S. V. (2013) Discovery of a chemical probe for the L3MBTL3 methyllysine reader domain Nat. Chem. Biol. 9, 184-191
24. Simhadri, C., Daze, K. D., Douglas, S. F., Quon, T. T., Dev, A., Gignac, M. C., Peng, F., Heller, M., Boulanger, M. J., Wulff, J. E., and Hof, F. (2014) Chromodomain antagonists that target the Polycomb-Group methyllysine reader protein Chromobox Homolog 7 (CBX7) J. Med. Chem. 57, 2874-2883
25. Wagner, E. K., Nath, N., Flemming, R., Feltenberger, J. B., and Denu, J. M. (2012) Identification and characterization of small molecule inhibitors of a plant homeodomain finger Biochemistry 51, 8293-8306
26. Miller, T. C., Mieszczanek, J., Sanchez-Barrena, M., Rutherford, T. J., Fiedler, M., and Bienz, M. (2013) Evolutionary adaptation of the fly Pygo PHD finger towards recognizing histone H3 tail methylated at arginine 2 Structure 21, 2208-2220
27. Nakamura, Y., Umehara, T., Hamana, H., Hayashizaki, Y., Inoue, M., Kigawa, T., Shirouzu, M., Terada, T., Tanaka, A., Padmanabhan, B., and Yokoyama, S. (2007) Crystal structure analysis of the PHD domain of the transcription co-activator Pygopus J. Mol. Biol. 370, 80-92
28. Pena, P. V., Davrazou, F., Shi, X., Walter, K. L., Verkhusha, V. V., Gozani, O., Zhao, R., and Kutateladze, T. G. (2006) Molecular mechanism of histone H3K4me3 recognition by plant homeodomain of ING2 Nature 442, 100-103
29. Taverna, S. D., Li, H., Ruthenburg, A. J., Allis, C. D., and Patel, D. J. (2007) How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers Nat. Struct. Mol. Biol. 14, 1025-1040
30. Hajduk, P. J. and Greer, J. (2007) A decade of fragment-based drug design: strategic advances and lessons learned Nat. Rev. Drug Discovery 6, 211-219
31. Murray, C. W. and Rees, D. C. (2009) The rise of fragment-based drug discovery Nat. Chem. 1, 187-192
32. Silvestre, H. L., Blundell, T. L., Abell, C., and Ciulli, A. (2013) Integrated biophysical approach to fragment screening and validation for fragment-based lead discovery Proc. Natl. Acad. Sci. U. S. A. 110, 12984-12989
33. Hajduk, P. J., Huth, J. R., and Fesik, S. W. (2005) Druggability indices for protein targets derived from NMR-based screening data J. Med. Chem. 48, 2518-2525
34. Basse, N., Kaar, J. L., Settanni, G., Joerger, A. C., Rutherford, T. J., and Fersht, A. R. (2010) Toward the rational design of p53-stabilizing drugs: probing the surface of the oncogenic Y220C mutant Chem. Biol. 17, 46-56
35. Welsch, M. E., Snyder, S. A., and Stockwell, B. R. (2010) Privileged scaffolds for library design and drug discovery Curr. Opin. Chem. Biol. 14, 347-361
36. Barelier, S. and Krimm, I. (2011) Ligand specificity, privileged substructures and protein druggability from fragment-based screening Curr. Opin. Chem. Biol. 15, 469-474
37. Duarte, C. D., Barreiro, E. J., and Fraga, C. A. (2007) Privileged structures: a useful concept for the rational design of new lead drug candidates Mini Rev. Med. Chem. 7, 1108-1119
38. Smith, S. G., Sanchez, R., and Zhou, M. M. (2014) Privileged Diazepine Compounds and Their Emergence as Bromodomain Inhibitors Chem. Biol. 21, 573-583
39. Dominguez, C., Boelens, R., and Bonvin, A. M. (2003) HADDOCK: a protein-protein docking approach based on biochemical or biophysical information J. Am. Chem. Soc. 125, 1731-1737
40. Ramon-Maiques, S., Kuo, A. J., Carney, D., Matthews, A. G., Oettinger, M. A., Gozani, O., and Yang, W. (2007) The plant homeodomain finger of RAG2 recognizes histone H3 methylated at both lysine-4 and arginine-2 Proc. Natl. Acad. Sci. U. S. A. 104, 18993-18998
41. Mori, S., Abeygunawardana, C., Johnson, M. O., and van Zijl, P. C. (1995) Improved sensitivity of HSQC spectra of exchanging protons at short interscan delays using a new fast HSQC (FHSQC) detection scheme that avoids water saturation J. Magn. Reson. B 108, 94-98
42. Dalvit, C., Fogliatto, G., Stewart, A., Veronesi, M., and Stockman, B. (2001) WaterLOGSY as a method for primary NMR screening: practical aspects and range of applicability J. Biomol. NMR 21, 349-359
43. Brunger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., Read, R. J., Rice, L. M., Simonson, T., and Warren, G. L. (1998) Crystallography & NMR system: A new software suite for macromolecular structure determination Acta Crystallogr., Sect. D: Biol. Crystallogr. 54, 905-921
44. Schuttelkopf, A. W. and van Aalten, D. M. (2004) PRODRG: a tool for high-throughput crystallography of protein-ligand complexes Acta Crystallogr., Sect. D: Biol. Crystallogr. 60, 1355-1363
45. McCoy, A. J., Grosse-Kunstleve, R. W., Storoni, L. C., and Read, R. J. (2005) Likelihood-enhanced fast translation functions Acta Crystallogr., Sect. D: Biol. Crystallogr. 61, 458-464